Mix this medicated feed (Type B) with non-medicated feed ingredients to make a Type C medicated feed as follows: Type C Medicated Feed Tiamulin grams/ton Feed Pounds Medicated Feed (Type B) Pounds Non-medicated Feed* 35 3.5 1996.5 200 20 1980 *When making an approved Type C medicated feed drug combination, the inclusion rate of this non-medicated feed should be adjusted for the amount of the other drug added to ma...
Store at or below 25°C (77°F). Temporary excursions to 40°C (104°F) permitted. To report adverse effects, access medical information, or obtain additional product information call 1-800-428-4441 For a complete listing of adverse reactions for DENAGARD reported to CVM see: www.fda.gov/reportanimalae Denagard, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Restricted Drug (California): ...
www.fda.gov/reportanimalaeType B Medicated
Swine Feed
For Manufacture of Type C medicated swine feed only.
Do not feed undiluted.
| Indications | Amount of Type B Medicated Feed Per Ton of Feed | Tiamulin hydrogen fumarate in Complete Type C Medicated Feed Per Ton | Withdrawal Period (days) |
| For treatment of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hyodysenteriae susceptible to Tiamulin | 20 lb | 200 g | 7 |
| For control of porcine proliferative enteropathies (ileitis) associated with Lawsonia intracellularis | 3.5 lb | 35 g | 2 |
| For control of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema) hyodysenteriae susceptible to Tiamulin | 3.5 lb | 35 g | 2 |
Observe withdrawal time shown in table above.
Keep out of reach of children. Avoid contact with skin. Direct contact with skin or mucous membranes may cause irritation.
Caution:
Do not feed undiluted. Do not use in feeds for animals other than swine. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined. Swine being treated with Denagard (tiamulin) should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin and semduramicin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.
Mix this medicated feed (Type B) with non-medicated feed ingredients to make a Type C medicated feed as follows:
| Type C Medicated Feed Tiamulin grams/ton Feed | Pounds Medicated Feed (Type B) | Pounds Non-medicated Feed* |
| 35 | 3.5 | 1996.5 |
| 200 | 20 | 1980 |
*When making an approved Type C medicated feed drug combination, the inclusion rate of this non-medicated feed should be adjusted for the amount of the other drug added to make such combination Type C medicated feed.
Store at or below 25°C (77°F). Temporary excursions to 40°C (104°F) permitted.
To report adverse effects, access medical information, or obtain additional product information call 1-800-428-4441
For a complete listing of adverse reactions for DENAGARD reported to CVM see: www.fda.gov/reportanimalae
Denagard, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
Restricted Drug (California): Use only as directed.
Approved by FDA under NADA # 139-472
Marketed by:
Elanco US, Inc.
Greenfield, IN 46140
Elanco™
BG101792X
Denagard™ 10
(tiamulin hydrogen fumarate)
Type B Medicated
Swine Feed
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 58198-7400 | 58198-7400-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| tiamulin fumarate | ION1Q02ZCX | ACTIB |
Adverse event summaries are temporarily unavailable. Other product information remains available.